Home

CHARLES M BAUM

CIK 1579824 · Founder, President, and CEO · last filed 2026-06-22

CHARLES M BAUM is a Founder, President, and CEO who has filed 72 SEC Form 4 insider transactions across 5 companies since 2013. The most recent filing, for ACRV, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$47.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $19.7K across reported positions. 11 SEC filings were submitted jointly with ARRAY BIOPHARMA INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$19.7K

Companies

5

Total Filings

72

Lifetime Open-Market Net

-$47.82M

Filer Profile

Reported Address
C/O MIRATI THERAPEUTICS INC.
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO, CA 92121
Related Filers
ARRAY BIOPHARMA INC — 11 joint filings, latest 2019-07-30
Tango Therapeutics, Inc. — 1 joint filings, latest 2020-09-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACRV Director 9,366 $2.10 $19.7K $0 5 2026-06-22
PMVP Director — $1.34 — $0 7 2026-06-05
Poseida Therapeutics, Inc. (PSTX) Delisted Director 0 $9.50 $0 $0 4 2025-01-08
Mirati Therapeutics, Inc. (MRTX) Delisted Founder, President, and CEO 114,482 $58.70 $6.72M -$47.82M 42 2024-01-23
IMMUNOMEDICS INC (IMMU) Delisted Director 0 — — $0 4 2020-10-23

Recent Filings

72 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-22 ACRV Grant (A) — $0 EDGAR
2026-06-05 PMVP Grant (A) — $0 EDGAR
2026-05-20 ACRV Grant (A) +9,366 $0 EDGAR
2025-06-17 ACRV Grant (A) — $0 EDGAR
2025-06-09 PMVP Grant (A) — $0 EDGAR
2025-01-08 Poseida Therapeutics, Inc. (PSTX) Delisted Mixed −78,600 $0 EDGAR
2024-06-24 ACRV Grant (A) — $0 EDGAR
2024-06-18 Poseida Therapeutics, Inc. (PSTX) Delisted Grant (A) +19,650 $0 EDGAR
2024-06-10 PMVP Grant (A) — $0 EDGAR
2024-01-23 Mirati Therapeutics, Inc. (MRTX) Delisted Disp (D) −237,871 $0 EDGAR
Showing 1–10 of 72
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.